Article
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Oct 2016
Younossi Zobair M, Stepanova Maria, Sulkowski Mark, Foster Graham R, Reau Nancy, Mangia Alessandra, Patel Keyur, Bräu Norbert, Roberts Stuart K, Afdhal Nezam, Nader Fatema, Henry Linda, Hunt Sharon
Abstract excerpt
BACKGROUND: Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks. The impact of RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs) of patients with genotype 2 and 3 has not been described. METHODS: PROs data were collected from participants...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.